Evidence map›Paper›PMID 34323286›Full record

ArticleEuropean journal of immunology2021

Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.

Jasper Rip, Marjolein J W de Bruijn, Stefan F H Neys, Simar Pal Singh, Jonas Willar, Jennifer A C van Hulst, Rudi W Hendriks, Odilia B J Corneth

Open access · hybridAbstract read
In one paragraph

Article in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jasper RipDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-5780-9271
Marjolein J W de BruijnDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Stefan F H NeysDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Simar Pal SinghDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Jonas WillarDepartment of Biology, Institute of Genetics, University of Erlangen-Nuremberg, Erlangen, Germany.
Jennifer A C van HulstDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2291-0382
Odilia B J CornethDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-8375-0506
Erasmus MC · NLFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton's tyrosine kinase (Btk) is a crucial signaling molecule in BCR signaling and a key regulator of B- cell differentiation and function. Btk inhibition has shown impressive clinical efficacy in various B-cell malignancies. However, it remains unknown whether inhibition additionally induces changes in BCR signaling due to feedback mechanisms, a phenomenon referred to as BCR rewiring. In this report, we studied the impact of Btk activity on major components of the BCR signaling pathway in mice. As expected, NF-κB and Akt/S6 signaling was decreased in Btk-deficient B cells. Unexpectedly, phosphorylation of several proximal signaling molecules, including CD79a, Syk, and PI3K, as well as the key Btk-effector PLCγ2 and the more downstream kinase Erk, were significantly increased. This pattern of BCR rewiring was essentially opposite in B cells from transgenic mice overexpressing Btk. Importantly, prolonged Btk inhibitor treatment of WT mice or mice engrafted with leukemic B cells also resulted in increased phosho-CD79a and phospho-PLCγ2 in B cells. Our findings show that Btk enzymatic function determines phosphorylation of proximal and distal BCR signaling molecules in B cells. We conclude that Btk inhibitor treatment results in rewiring of BCR signaling, which may affect both malignant and healthy B cells.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAnimalsAntineoplastic AgentsBenzamidesB-LymphocytesCD79 AntigensExtracellular Signal-Regulated MAP KinasesImmunoglobulin MLymphoma, B-CellMiceMice, Inbred C57BLMice, KnockoutNF-kappa BPhosphatidylinositol 3-KinasesPhospholipase C gammaPhosphorylationacalabrutinibAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBenzamidesCD79 AntigensCd79a protein, mouseExtracellular Signal-Regulated MAP KinasesImmunoglobulin MNF-kappa BPhosphatidylinositol 3-KinasesPhospholipase C gammaProto-Oncogene Proteins c-aktPyrazinesReceptors, Antigen, B-CellSyk KinaseSyk protein, mouseAcalabrutinibB cellBCR signalingBruton′s tyrosine kinasePhosphoflow cytometry

Identifiers

PMID34323286
PMCPMC9291019
OpenAlexW3183742907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.